Analysts have clear opinions on CTMX.
There are 3 analysts on the Wall offering 12 month price targets for CytomX Therapeutics in the last 3 months. The average price target is $15.67 with a high forecast of $17.00 and a low forecast of $14.00. The average price target represents a 122.90% increase from the last price of $7.03.
CytomX Therapeutics, Inc. (CTMX) is followed by 3 analysts on the street.
Etzer Darout from Guggenheim rates it a Buy with a target of $17.00.
Similarly, 2 months ago Ram Selvaraju of H.C. Wainwright Reiterated a Buy with a target of $14.00.
The consensus on the street is null.
What does CytomX Therapeutics, Inc.(CTMX) do ?
CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
CytomX Therapeutics, Inc. (CTMX) Insider Trades
Looking for stocks just like CTMX?
Based on Wall Street analyst research, several stocks are similar to CTMX
– PFE [Info can be found here: https://www.nasdaq.com/market-activity/stocks/PFE ]
– BMY [Info can be found here: https://www.nasdaq.com/market-activity/stocks/BMY ]
– IMGN [Info can be found here: https://www.nasdaq.com/market-activity/stocks/IMGN ]